Erschienen in:
30.10.2017 | Thoracic Oncology
Comments on “An Investigation into the Serum Thioredoxin, Superoxide Dismutase, Malondialdehyde, and Advanced Oxidation Protein Products in Patients with Breast Cancer”
verfasst von:
Maryam Khoubnasabjafari, MD, PhD, Khalil Ansarin, MD, Abolghasem Jouyban, PharmD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2017
Einloggen, um Zugang zu erhalten
Excerpt
In an article by Kilic et al., published in this journal, serum thioredoxin, superoxide dismutase, malondialdehyde (MDA), and advanced oxidation protein products in breast cancer patients and those of healthy controls were measured.
1 Further statistical analysis revealed an increased MDA level in the patient group.
1 The findings about MDA agree with some previously reported data and disagree with other reports. The purpose of this communication is not to criticize the valuable work of Kilic et al. but rather to highlight wide variations of MDA levels and to note some considerations on sample collection, confounding factors on MDA level, the validity of its measurement methods, and reliability of MDA as a biomarker in cancer. …